OXFORD, UK – 17 June 2026 – PrecisionLife has launched Biology Matters, a new podcast exploring how advances in biology, genomics, data science, and AI can help address one of healthcare's greatest challenges: chronic disease.
The podcast's debut episode features hosts and PrecisionLife co-founders Steve and Rowan Gardner discussing the growing impact of chronic disease on patients, healthcare systems, and society, and the opportunities emerging from advances in precision medicine.
Future episodes will feature leaders from across healthcare, biopharma, technology, research, and patient communities. Early discussions include healthcare transformation and prevention, as well as the growing opportunity to improve outcomes in women's health through better understanding of disease biology.
"Healthcare as we know it is unsustainable. Overwhelmed by complex, chronic diseases which account for the majority of healthcare spending in systems that are largely designed to react to illness rather than prevent it," said Steve Gardner, CEO and Co-Founder of PrecisionLife. "Biology Matters brings together leaders from healthcare, research, biotech, patient advocacy, and policy to explore how better understanding disease biology can help us predict risk earlier, personalize care, and reduce the burden of chronic disease."
PrecisionLife is a precision medicine company pioneering the use of AI-driven combinatorial analytics to identify the biological mechanisms driving complex chronic diseases. The company's approach helps healthcare providers, payors, and biopharma organizations better predict disease risk, stratify patients, improve treatment selection, and discover new therapeutic opportunities.
New episodes of Biology Matters will be released every two weeks and are available on Apple Podcasts, Spotify, YouTube, and other major podcast platforms.
For more information, visit precisionlife.com.
-- ENDS --
PrecisionLife is driving a new era of precision medicine to predict, treat, and prevent chronic diseases which account for over 80% of healthcare costs. Its world-leading AI and combinatorial analysis platform reveals the deepest biological insights into complex diseases and translates them into next generation precision medicine solutions. With these innovations, PrecisionLife is enabling healthcare providers, payors, and pharmaceutical companies to improve outcomes, reduce waste, and build more sustainable models of care for the billions of people affected by chronic diseases.
For more information:
Visit: precisionlife.com
Contact: press@precisionlife.com
Follow: PrecisionLifeAI